We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals

74 hedge funds and large institutions have $136M invested in Verrica Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

621% more call options, than puts

Call options by funds: $584K | Put options by funds: $81K

156% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 9

29% more capital invested

Capital invested by funds: $105M → $136M (+$30.8M)

23% more funds holding

Funds holding: 6074 (+14)

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

0.21% more ownership

Funds ownership: 4.18%4.4% (+0.21%)

Holders
74
Holders Change
+14
Holders Change %
+23.33%
% of All Funds
1.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
17
Reduced
16
Closed
9
Calls
$584K
Puts
$81K
Net Calls
+$503K
Net Calls Change
+$524K
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
76
Goldman Sachs
New York
-$116K -1,956 Closed
LT
77
Legacy Trust
Michigan
-$111K -1,875 Closed
Dimensional Fund Advisors
78
Dimensional Fund Advisors
Texas
-$69K -1,165 Closed
AIG
79
American International Group
New York
-$60.9K -1,029 Closed
Simplex Trading
80
Simplex Trading
Illinois
-$17.6K -229 Closed
Group One Trading
81
Group One Trading
Illinois
-$5.38K -70 Closed
OPTFSNA
82
Old Point Trust & Financial Services N A
Virginia
-$2.96K -50 Closed
AWM
83
Avior Wealth Management
Nebraska
-$23
Carson Wealth (CWM LLC)
84
Carson Wealth (CWM LLC)
Nebraska
+$77 +1 New

VRCA Hedge Fund Activity: Q2 2024 in Review

74 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2024, worth a combined $136M — up 29% from $105M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new VRCA positions and 9 closed out — a net gain of 14 holders — while 17 added to existing stakes and 16 trimmed.

The largest buyer was Propel Bio Management, opening a new position worth an estimated $3.26M. The largest seller was Fidelity Investments, cutting an estimated $3.08M.

  • 74 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2024, up from 60 in Q1 2024.
  • Funds reported $136M of Verrica Pharmaceuticals stock for Q2 2024, up 29% quarter-over-quarter.
  • 23 funds opened new Verrica Pharmaceuticals positions in Q2 2024 and 9 closed out, a net change of +14 holders.
  • The largest Verrica Pharmaceuticals buyer in Q2 2024 was Propel Bio Management, an estimated $3.26M added.
  • The largest Verrica Pharmaceuticals seller in Q2 2024 was Fidelity Investments, an estimated $3.08M sold.

Based on aggregated 13F filings for Q2 2024.